UroGen Pharma Ltd logo

UroGen Pharma Ltd

$ 9.27 -1.75 (-15.88%) 11:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 214.04M
Enterprise V:
$ 191.86M
Volume:
141.35K
Avg Vol (2M):
94.66K
Also Trade In:
Volume:
141.35K
Market Cap $:
214.04M
PE Ratio:
At Loss
Avg Vol (2-Month):
94.66K
Enterprise Value $:
191.86M
PB Ratio:
0

Business Description

Description
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Name Current Vs Industry Vs History
Cash-To-Debt 1.3
Equity-to-Asset -0.49
Debt-to-Equity -1.17
Debt-to-EBITDA -0.89
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.47
Distress
Grey
Safe
Beneish M-Score -3.52
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 41.59
9-Day RSI 49.97
14-Day RSI 52.34
6-1 Month Momentum % 13.68
12-1 Month Momentum % 21.86

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.4
Quick Ratio 6.14
Cash Ratio 5.05
Days Inventory 243.73
Days Sales Outstanding 58.49
Days Payable 199.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -11.5